Updated:
Audentes Therapeutics
Audentes Therapeutics is a San Francisco-based biotechnology firm developing gene therapies for neuromuscular diseases, acquired by Astellas Pharma in...
Audentes Therapeutics
Audentes Therapeutics was founded with the mission of advancing gene therapy for severe neuromuscular disorders, leveraging adeno-associated virus (AAV) vector technology to deliver functional copies of faulty genes. The firm's platform concentrates on monogenic diseases where a single gene defect drives pathology, allowing for a targeted therapeutic approach. Wealth origin and founding investors remain undisclosed in public records. The company's research and development pipeline includes programs for X-linked myotubular myopathy (XLMTM), Pompe disease, and other neuromuscular conditions. Audentes has disclosed clinical trial data for its lead candidate, AT132, an AAV8-based gene therapy for XLMTM, in peer-reviewed publications and regulatory filings. Geographically, the firm operates primarily in North America, with clinical sites potentially extending to Europe and other regions through trial partnerships. Audentes employed a workforce of several hundred professionals at its San Francisco headquarters, with additional operational capacity implied by its clinical-stage activities. Team size and specific leadership structures have not been consistently documented in public sources. A notable operational event occurred in 2020 when Astellas Pharma acquired Audentes for approximately $3 billion, integrating the firm into its gene therapy portfolio and signaling the pharmaceutical sector's appetite for neuromuscular gene therapy platforms. The firm's structural differentiator lies in its focus on a single vector technology (AAV) applied across multiple rare diseases, creating a platform that can potentially be replicated for new indications. This model contrasts with diversified biotech firms that spread resources across modalities. Audentes' acquisition by Astellas further highlights how specialized gene therapy developers serve as strategic assets for larger pharmaceutical companies seeking to expand their genetic medicine capabilities.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
What is the primary therapeutic focus of Audentes Therapeutics?
Audentes Therapeutics concentrates on developing gene therapies for serious neuromuscular diseases, particularly those caused by single-gene mutations. Its lead programs address X-linked myotubular myopathy (XLMTM) and Pompe disease, using AAV vector technology to deliver corrected genes to patient cells (per the firm's clinical trial disclosures, 2020).
Who acquired Audentes Therapeutics, and why?
Astellas Pharma acquired Audentes Therapeutics in December 2020 for approximately $3 billion. The acquisition aimed to strengthen Astellas' gene therapy pipeline by incorporating Audentes' AAV-based platform and neuromuscular disease expertise, reflecting a broader trend of pharmaceutical companies purchasing specialized gene therapy developers.
What gene therapy technology does Audentes use?
Audentes employs adeno-associated virus (AAV) vectors, specifically AAV8 serotype, to deliver therapeutic transgenes. This approach targets monogenic diseases where replacing a missing or defective gene can address the root cause of the disorder. The company's platform has been tested in clinical trials for XLMTM and other indications.
Has Audentes Therapeutics advanced any drug candidates to regulatory approval?
As of public records, Audentes' lead candidate AT132 for XLMTM had not received regulatory approval before the acquisition. The candidate was in clinical trials but faced challenges, including safety concerns related to liver toxicity. Post-acquisition, development continues under Astellas Pharma's oversight.
Is Audentes Therapeutics still an independent company?
No, Audentes Therapeutics is no longer an independent entity. It was acquired by Astellas Pharma in December 2020 and now operates as a wholly owned subsidiary within Astellas' gene therapy unit. The San Francisco headquarters remains active, but strategic and operational decisions are now integrated into Astellas' broader R&D structure (per Astellas press release, December 2020).
What rare diseases does Audentes' pipeline target?
Audentes' pipeline primarily targets X-linked myotubular myopathy (XLMTM), a severe congenital neuromuscular disorder, and Pompe disease, a glycogen storage disorder affecting muscle function. Both conditions are rare, monogenic, and have high unmet medical need. Additional preclinical programs may address other neuromuscular indications.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: